Eila Arich-Landkof, founder - Entrepreneur at the Computer Science & Life Science Industries. Served in a variety of positions at the high tech industry and at the life science industry. Worked for leading companies such as: Cisco, Microsoft, Elbit systems, The Whitehead institute of biomedical research, Mass General Hospital and the Broad Institute of Harvard and MIT. BA in math & computer science, MA in quality assurance and reliability.

Eila navigated her career from the hightech industry to the life science industry and the research field. She worked as a developer, team leader, product manager, startup founder, wet lab technician, cancer genomic researcher & product manager. Eila envisioned tumor portal role in the cancer healthcare world and has been able to transfer her vision into reality. Her effort and vision was acknowledged at the 2016 Broad annual scientific contest where tumor portal won the first place in its category.

Currently Eila leads the Deep-Learning-in-Production meetup (~1900 members) and the Founder and CEO of Oriel Research

Dr. Noam Shoresh, PhD, advisor

Noam Shoresh is an associate director of computational biology at the Broad Institute of Harvard and MIT in the Epigenomics program, and also oversees computational projects in the program of infectious diseases at the Broad Institute. Dr. Shoresh was trained as a theoretical physicist in the field of elementary particles. Following that, he was training as a postdoctoral fellow at Harvard in the field of computational biologist. At 2008, Dr. Shoresh joined the Broad Institute.

Dr. Shoresh's epigenomics computational team has made central contributions to ENCODE project aimed at the characterization of the human epigenome in health and disease. Dr. Shoresh's expertise also includes the evolution and adaptation of microorganisms, with a focus on the emergence of resistance and tolerance to antibiotic treatments.

Dr. Shoresh publications are available on pubmed

Dr. Keren Yizhak, PhD, advisor

Keren Yizhak is a post-doctoral fellow at the Getz lab, Broad Institute of Harvard and MIT. Dr. Yizhak work at the Getz and Hacohen lab has break through results in understanding cancer initiation and its immune response.

Dr. Yitzhak current work is focused on novel sequencing data, bulk and single-cell RNA-seq, analysis. Prior to joining the Broad Institute, Dr. Yizhak was a graduate student at Tel-Aviv University at the Computer Science department, where she developed tools for studying human metabolism on a genome-scale. Dr. Yizhak’s honors include the Klarman fellowship and the Weizmann award for advancing women in science.

Dr. Yizhak papers publications are available on pubmed

Dr. Rotem Ben-Hamo Deutsch, PhD, advisor

Rotem Ben-Hamo Deutsch is a post-doctoral fellow at the Getz lab, Broad Institute of Harvard and MIT and at the Straussman lab, Weizmann Institute of Science. Dr. Ben-Hamo has a deep understanding in drug resistance mechanisms, systems biology and metabolism on a genome-scale. Dr. Ben-Hamo current work focuses on the prediction of drug sensitivity in a systems-based manner using protein-protein interaction networks and signaling pathways.

Dr. Ben-Hamo completed her computational biology master degree Summa Cum Laude at Bar-Ilan University. Dr. Ben-Hamo’s was granted for the Rothschild fellows and the Dean of faculty fellowship.

Dr. Ben-Hamo papers publications are available on pubmed

Dr. Lior Braunstein, MD, advisor

A radiation oncologist specializes in caring for people with breast cancer, primary and metastatic brain tumors, prostate cancer, bladder cancer, kidney cancer, and testicular cancer. Dr. Braunstein has expertise in using advanced radiation therapy techniques such as intensity-modulated radiation therapy, image-guided radiation therapy, stereotactic body radiation therapy, and stereotactic radiosurgery. Dr. Braunstein guides patients through every aspect of their care, from diagnosis through treatment and into long-term follow-up and Memorial Sloan Kettering Cancer Center in NY.

Dr. Braunstein publications are available on pubmed